| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | $132.0M-38.8% | $215.7M-17.6% | $261.8M-8.4% | $285.9M+15.0% | $248.6M |
| Research and development related success payments and contingent consideration | $29.4M+431.4% | -$8.9M+81.9% | -$49.0M+42.3% | -$84.9M-246.7% | $57.9M |
| General and administrative | $44.3M-30.8% | $64.0M-12.6% | $73.3M+2.4% | $71.6M+42.0% | $50.4M |
| Impairment of long-lived assets | $44.6M+2259.1% | $1.9M-73.0% | $7.0M | — | — |
| Total operating expenses | $250.3M-8.2% | $272.7M-7.0% | $293.1M+7.5% | $272.6M-23.6% | $356.9M |
| Loss from operations | -$250.3M+8.2% | -$272.7M+7.0% | -$293.1M-7.5% | -$272.6M+23.6% | -$356.9M |
| Interest income, net | $3.8M-63.3% | $10.5M+5.4% | $9.9M+164.2% | $3.8M+456.5% | $676K |
| Other income (expense), net | $2.3M+151.1% | -$4.5M-8567.3% | -$52K+92.3% | -$674K-321.0% | $305K |
| Net loss | -$244.2M+8.5% | -$266.8M+5.8% | -$283.3M-5.1% | -$269.5M+24.3% | -$355.9M |
| Net loss per common share - basic | -$960.00+17.2% | -$1160.00+20.5% | -$1460.00-101997.9% | -$1.43+33.2% | -$2.14 |
| Net loss per common share - diluted | -$960.00+17.2% | -$1160.00+20.5% | -$1460.00-101997.9% | -$1.43+33.2% | -$2.14 |
| Weighted-average number of common shares - basic | 253.2M+9.7% | 230.9M+18.7% | 194.5M+3.3% | 188.3M+13.2% | 166.4M |
| Weighted-average number of common shares - diluted | 253.2M+9.7% | 230.9M+18.7% | 194.5M+3.3% | 188.3M+13.2% | 166.4M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.